Die derzeit wohl interessanteste Bioaktie - 500 Beiträge pro Seite

[The early BIRD]

Generex Biotech-GNBT-922012- ist derzeit wohl die interessanteste Bioaktie.

Das Unternehmen hat ein Mittel für Zuckerkranke, das oral eingenommen werden kann, entwickelt.
Was das bedeutet, können am Besten zwar Zuckerkranke beurteilen, die ihr Leben lang Insulin spritzen m
üssen, aber ich denke, es ist eine bahnbrechende Sache.
Gestern kam die Meldung, daß Ely Lilly das Medikament vermarktet.
Heute kam die News, daß eine Investorengruppe 50 Mio Us Dollar investiert und eine Beteiligung eingeht.
Die Aktie notiert derzeit in N.Y. knapp bei 20 USD.
Der Platowbrief wird in seiner morgigen Ausgabe darüber berichten und empfiehlt sich einige Stücke hinzulegen, wenn
die Aktie konsolidiert und ein wenig zurückkommt.Ich denke interessante Aktien sind nie preiswert und die
Aktie steht vor einer absoluten Neubewertung.
Ich bin sicher, daß in Kürze hier in Deutschland durch bekannte Publizisten die Aktie aufgegriffen wird und extrem gepusht wird.
Jeder sollte sich selbst ein Bild machen.Mein kurzfristiges Kursziel liegt bei 48 USD.
Viel Glück
Cheftrader

[WIWALDI]

Sehe ich genauso! Generex habe ich auch heute entdeckt. Bin der Meinung die Story stimmt.
Guter Chart und noch keine Puschs durch Börsenbriefe usw. (Ausn. heutige Platow-Meldung)

[gholzbauer]

UPDATE 1-Lilly to advance Generex oral insulin spray
(Recasts with background, additional comments, throughout)
By Ian Karleff


TORONTO, Sept 6 (Reuters) - Diabetics may be a step closer to doing without pesky insulin injections following Wednesday`s announcement that Eli Lilly and Co. will steward the development of an oral insulin spray.

Toronto-based Generex Biotechnology Corp. (NASDAQ: GNBT) said on Wednesday that U.S. drugs manufacturer Eli Lilly (NYSE: LLY) has agreed to market its oral insulin spray for diabetes, which is similar to sprays used to control asthma.

In exchange, Lilly will pay for the last stages of clinical trials and the securing of regulatory approvals.

With the deal, Eli Lilly attempts to keep its share of an estimated $200 billion market for diabetes treatments by joining the race to introduce new and easier delivery methods.

Its rivals are also looking for alternatives to insulin injections. Pfizer Inc. (NYSE: PFE), Lilly`s main competitor in the insulin market, has joined Aventis SA to develop an inhalable insulin.

The Lilly agreement is an important step for Generex because it secures a supply of insulin for its RapidMist spray from the world`s largest insulin producer.

"Lilly is the world`s largest producer of insulin and we need human crystal insulin to formulate our spray...so to have a partner that has this kind of capacity for product is crucial," said Generex chief executive Anna Gluskin.

The companies hope the insulin spray, which is absorbed in the cheek lining, will improve the diabetic`s quality of life by avoiding injections. In in turn improve compliance with treatment regimens and prevent complications associated with the ailment.

"A buccal (absorption through the inner cheek walls) spray formulation of insulin could provide an attractive alternative for people with diabetes," said James Harper, Eli Lilly`s president of diabetes and growth disorders, in a statement.

Dr. Knam Vay Ung, a specialist in diabetes management, told Reuters that millions of people would welcome an alternative to injections and that such an alternative would surely improve compliance with insulin regimens.

"A lot of people don`t like the sight of needles and they have to be in a private place, but if they`re inhaling they can do it anywhere. Anything to make it more compliant is great," Ung said.

Generex said it will receive initial fees and milestone payments from Lilly. Royalty payments would come if and when the insulin delivery system is approved for marketing.

Neither Lilly nor Generex would reveal the terms of the financial agreement.

Gluskin said Generex has spent upward of $25 million to develop the insulin delivery system, and it would cost more than $40 million to bring it to market.

Over the past few months Generex has been securing supply agreements for its eventual launch of RapidMist. Britain`s Presspart will supply the components for the company`s device, while an AptarGroup (NYSE: ATR)subsidiary will supply a dispensing valve.

Shares of Generex opened higher on Nasdaq but were off $2-1/8 at $20-1/4 in mid-morning trading.

Eli Lilly was trading down $1-9/16 at $68-5/16 on the New York Stock Exchange.

"We have closed the loop - we have a supply of insulin for our product, and supply of the parts for the device and now we have to go into the development process," said Gluskin.

Gluskin declined to comment on when RapidMist could gain regulatory approval under the stewardship of Lilly.

Competitor Aventis told Reuters in July that its inhalable insulin, which is absorbed in the lungs, is in late stages of clinical trials and could win regulatory approval in two years.

($1=$1.48 Canadian)

[gholzbauer]

GENEREX BIOTECHNOLOGY CORP - Lilly and Generex Sign Agreement To Develop Buccal Form of Insulin
Eli Lilly and Company and Generex Biotechnology Corporation announced

that they have signed an agreement to develop a buccal formulation of insulin that is administered as a fine spray into the oral cavity using Generex proprietary technology.

Toronto, Ontario, Sep. 06, 2000 (Market News Publishing via COMTEX) -- Under the terms of the agreement, Generex will receive certain initial fees and milestone payments. Generex will also receive royalty payments based on product sales. In exchange, Lilly will receive exclusive worldwide rights to products resulting from the collaboration. Lilly will be responsible for conducting clinical trials, securing regulatory approvals and marketing on a worldwide basis. Clinical trials of the first product candidate are under way in North America and Europe. Lilly will also have the option to develop a number of additional products depending on the success of the initial product.

"We look forward to working with Generex, whose buccal spray delivery technology potentially represents a novel approach to drug delivery," said James A. Harper, president, diabetes and growth disorders products for Lilly. "A buccal spray formulation of insulin could provide an attractive alternative for people with diabetes."

"The opportunity to partner with Lilly, the global leader in insulins, to develop the world`s first marketed buccal insulin spray represents very good news for millions of patients with diabetes throughout the world," said Anna Gluskin, chief executive officer of Generex. "We are pleased that Lilly has recognized the potential of buccal delivery of insulin and Generex`s RapidMist(TM) technology for systemic delivery of proteins, peptides and other large molecule drugs."

"Lilly has a long standing history in the area of diabetes which goes back to our collaboration with two Canadian physicians, Drs. Banting and Best, who discovered insulin to control diabetes in 1921," said Gaetano Crupi, President, Eli Lilly Canada Inc. "Research has always been the foundation of the pharmaceutical industry. It has become even more important as we enter a revolutionary era in the development of new medicines. Canada is positioned as a strong scientific player attracting global R&D investments and exporting Canadian technology. This is evidenced by today`s agreement between Lilly and Generex."

Today, worldwide costs for treating diabetes and its complications are estimated to exceed $200 billion annually. It is also estimated that, over the next decade, the number of people with this disease will more than double. Lilly has been a leader in diabetes care for more than 75 years. The company continues to aggressively pursue the goal of being a complete diabetes care company and intends to provide innovative products to treat all types and stages of diabetes.

Generex is engaged in the research and development of drug delivery systems and technologies. To date, it has focused on developing a platform technology for the buccal delivery (absorption through the inner cheek walls) of large molecule drugs which, historically, have been administered only by injection. Additional information about Generex can be found at www.generex.com.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world`s most urgent medical needs. Lilly Canada, headquartered in Toronto, Ontario, employs more than 600 people across the country.

[gholzbauer]

Generex Biotechnology Corporation Receives $50 Million Equity Line Commitment Arranged by Ladenburg Thalmann
TORONTO, Sep 7, 2000 /PRNewswire via COMTEX/ -- Generex Biotechnology Corporation (Nasdaq: GNBT chart, msgs), today announced that it has received a commitment from a private investment fund to purchase up to $50 million of Generex common stock. The commitment was arranged by investment banking firm Ladenburg Thalmann & Co.

Generex` right to draw upon this commitment is subject to a number of limitations and conditions, including a limitation on the amounts sold within specified periods and the condition that the shares be registered for resale by the investor at the time Generex elects to sell the shares. Because of these conditions and limitations, it is uncertain whether and to what extent Generex will be able to draw upon this facility. Subject to these conditions and limitations, Generex will have full control over the facility and is under no obligation to use it, i.e., to sell any shares. Pricing on shares that are sold will be based upon the volume weighted average market price of Generex common stock during a fixed period prior to the sale, and will not be below a floor price that Generex may establish in its discretion.

Generex President and Chief Executive Officer Anna Gluskin commented: "The availability of this equity line will allow us to pursue clinical programs and other research, development and commercialization efforts with financing in place. This kind of financing option is very attractive to us since it gives us complete flexibility over timing and a substantial degree of control over pricing."

The sale of shares by Generex pursuant to the equity drawdown facility will not be registered under the Securities Act of 1933. However, Generex will register the shares under the Securities Act for immediate resale by the investor.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities of Generex.

About Generex:

Generex Biotechnology Corporation is engaged in the research and development of drug delivery systems and technologies. To date, it has focused on developing a platform technology for the buccal delivery (absorption through the inner cheek walls) of large molecule drugs which, historically, have been administered only by injection. The Company`s first application for the technology is an insulin formulation (ORALGEN(TM) in the United States and ORALIN(TM) in Canada and elsewhere) that is administered as a fine spray into the oral cavity using RAPIDMIST(TM), a lightweight, hand held aerosol applicator. Phase II clinical trials of this product presently are in progress in the United States, Canada and Europe.